Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (29,877)	$ (26,817)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Depreciation and amortization	2,323	2,174
Amortization of convertible notes debt discount		4,389
Gain on debt extinguishment, net	(2,395)
Stock‑based compensation expense	3,677	155
Change in contingent consideration	1,622	957
Provision for doubtful accounts	193	113
Accrued interest, amortization of debt issuance costs and other	1,607	1,165
Changes in operating assets and liabilities:
Accounts receivable	12,327	(217)
Other current assets	2,866	(4,283)
Other long-term assets and liabilities	665	(5)
Accounts payable and other accrued liabilities	(9,262)	5,369
Deferred revenue	(1,772)	4,390
Net cash and cash equivalents and restricted cash used in operating activities	(18,026)	(12,610)
Cash flows from investing activities
Purchases of property and equipment	(1,711)	(1,483)
Patent costs and intangible asset acquisition, net	(195)	(151)
Payment to acquire Oncimmune assets		(750)
Net cash and cash equivalents and restricted cash used in investing activities	(1,906)	(2,384)
Cash flows from financing activities
Proceeds from issuance of convertible debt payable		12,955
Proceeds from issuance of common stock under employee stock purchase plan	328
Proceeds from exercise of stock options	739	25
Proceeds from term loan and notes payable	30,078	3,085
Repayment of term loan and notes payable	(25,424)
Payment of debt issuance costs	(96)
Other		(10)
Net cash and cash equivalents and restricted cash provided by financing activities	5,625	16,055
Net (decrease) increase in cash and cash equivalents and restricted cash	(14,307)	1,061
Cash, cash equivalents, and restricted cash ‑ beginning of period	62,306	5,469
Cash, cash equivalents, and restricted cash ‑ end of period	$ 47,999	$ 6,530